Overview

Bevacizumab, Chemotherapy and Valproic Acid in Advanced Sarcomas

Status:
Completed
Trial end date:
2017-08-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the combination of the chemotherapy drugs Gemcitabine, bevacizumab, and docetaxel with valproic acid to treat patients with metastatic sarcoma. Valproic acid is used by people who have seizures to prevent seizures from happening; however, its use in cancer is investigational. This study will help define the proper dosing of this valproic acid. We will assess the safety of valproic acid with the combination of the above chemotherapy drugs and check for possible side effects. Valproic acid may improve the function of the chemotherapy drugs against the cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Mohammed M Milhem
University of Iowa
Collaborator:
Genentech, Inc.
Treatments:
Bevacizumab
Docetaxel
Gemcitabine
Histone Deacetylase Inhibitors
Valproic Acid